Loading…
← CockpitCompetitor Analysis › CLDX Celldex Therapeutics, Inc.Open in the cockpit ↗

Celldex Therapeutics, Inc.CLDXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.

Momentum weak 26
Mkt cap
$2.16B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$25.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$27.55
1D-1.8%
1W-8.6%
1M-9.1%
3M-31.0%
6M-10.8%
YTD+1.4%
1Y+6.0%
ATR %5.2%
Beta1.25
52w lowhigh39.0% off high

What Celldex Therapeutics does

Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.

Has no product sales; trial costs are paid from money raised from investors. Barzolvolimab is in late-stage trials for chronic hives and related skin disorders, so the next steps are trial results and, if approved, building a sales force or finding a partner to sell it.

Products and services

  • Barzolvolimab (chronic urticaria/mast cell disorders)
  • Oncology antibody pipeline

Customers

  • Allergists/dermatologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Antibody therapeutics for mast…

What could go right

  • Pivotal trial data readouts
  • Large chronic urticaria market opportunity

What could go wrong

  • Clinical trial failure risk
  • Competitive allergic/mast-cell disease field

Moat: none (IP / patents). Clinical-stage biotech with a differentiated mast-cell-targeting antibody but no approved products yet.

Headquarters: Hampton, New Jersey, US · Founded: 1983 · Employees: 198

Named competitors

Celldex Therapeutics at a glance

Size Celldex Therapeutics (CLDX) is a United States Health Care company (Biotechnology) with a market value of $2.16B, the 1724th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.55 on 18 Nov 2026.

Performance Over six months the shares fell 10.8%, against -11.6% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue fell 93.9% over the last twelve months (peer median +4.1%); the operating margin is -211,684.8% (peer median -15.4%).

Valuation It trades at 9,677.0× enterprise value to sales against a peer median of 9.4× (most expensive of 15).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 92CLDX 90
Six months, rebased to 100: Celldex Therapeutics against the median of its 20 peers (local-currency closes).

Celldex Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$158,000$1.54M$7.02M$6.88M$2.36M
Revenue growth—-78%+2%+192%—
Gross profit-$3.58M-$1.83M$3.84M$3.88M$957,000
EBITDA-$331M-$284M-$192M-$139M-$106M
Net income-$309M-$259M-$158M-$141M-$112M
Free cash flow-$260M-$214M-$160M-$109M-$106M
Capital expenditure$7.77M$2.71M$1.92M$1.82M$1.83M
Total debt$9.87M$2.34M$3.81M$2.54M$4.03M

Quarterly statements and history in the cockpit →

Celldex Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%ZEALBEAMPVLA300676ALMRPHVS302440RCUSAUPH300255MRVIREPLCLDX6-month return →1-month return →
Up and to the right = strong over both horizons. Celldex Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×5,000×10,000×ZEALBEAM300676ALMR302440RCUS300142BCRXCLDXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Celldex Therapeutics is the large dot.

Celldex Therapeutics competitors and peer comparison

Head to head with its named competitors (CLDX vs AMGN vs COGT vs NOVN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Celldex Therapeutics CLDX$2.16B-11%-94%-211,685%9,677.0×n/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Cogent Biosciences COGT$4.84B-16%n/an/an/an/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Sanofi SAN.PA$114B+13%+15%27%2.6×-4.8%
Roche RO.SW$381B+21%-1%31%5.7×1.7%

How Celldex Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Celldex Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCLDXPeer medianRank in peer set
1-month return-9.1%-4.9%9th lowest of 21
6-month return-10.8%-11.6%10th highest of 20
Distance from 52-week high-39.0%-34.1%9th lowest of 21
Revenue growth (TTM)-93.9%+4.1%3rd lowest of 17
Operating margin-211,684.8%-15.4%lowest of 15
EV / Sales9,677.0×9.4×most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a

Questions

Who are Celldex Therapeutics's main competitors?
Named competitors: Amgen/AstraZeneca (Tezspire) (AMGN), Cogent Biosciences (COGT), Jasper Therapeutics (private or unlisted), Novartis (NOVN.SW), Sanofi (SAN.PA), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Zealand Pharma A/S (ZEAL.CO), Beam Therapeutics (BEAM), Palvella Therapeutics (PVLA), BGI Genomics (300676.SZ), Alamar Biosciences (ALMR), Pharvaris (PHVS).
Is Celldex Therapeutics expensive compared with its peers?
On ev / sales it trades at 9,677.0× against a peer median of 9.4×, most expensive of 15 in its peer set.
How has Celldex Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -10.8% against -11.6% for the median peer; over one year +6.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.